Results 181 to 190 of about 17,377 (218)

Therapy of ATTR amyloidosis: perspective

Amyloid, 2011
Abstract: Although liver transplantation is the only therapy to halt the clinical manifestations of transthyretin (TTR) related familial amyloidotic polyneuropathy (FAP), the therapy has given rise...
openaire   +2 more sources

Inotersen treatment for ATTR amyloidosis

Amyloid, 2019
Until recently there has been limited specific therapy for transthyretin amyloidosis (ATTR). One possible therapy is to reduce the availability of the protein precursor necessary for amyloid fibril...
openaire   +2 more sources

Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis

Amyloid, 2013
Abstract The clinical phenotype of familial ATTR amyloidosis depends to some extent on the particular mutation, but differences exist also within mutations. We have previously described that two types of amyloid fibril compositions exist among Swedish ATTRV30M amyloidosis patients, one consisting of a mixture of intact and fragmented ATTR (type A) and ...
Ihse E, RAPEZZI, CLAUDIO, MERLINI, GIOVANNI, Benson MD, Ando Y, Suhr OB, Ikeda SI, Lavatelli F, Obici L, QUARTA, CANDIDA CRISTINA, LEONE, ORNELLA, Jono H, Ueda M, LORENZINI, MASSIMILIANO, Liepnieks J, Ohshima T, Tasaki M, Yamashita T, Westermark P.   +18 more
openaire   +5 more sources

Stabilizing Transthyretin to Treat ATTR Cardiomyopathy

New England Journal of Medicine, 2018
Transthyretin amyloid cardiomyopathy is caused by intramyocardial deposition of transthyretin-derived amyloid fibrils, which leads to progressive ventricular wall thickening and stiffness of the heart. Once diagnosed, it is associated with a life expectancy of only 2 to 6 years.
C Cristina, Quarta, Scott D, Solomon
openaire   +2 more sources

Detection of ATTR aggregates in plasma of polyneuropathic ATTR-V30M amyloidosis patients

Abstract ATTR amyloidosis is caused by the deposition of transthyretin amyloid fibrils in tissues often leading to organ failure and death. The clinical spectrum of this disease is highly diverse and dependent on many factors including the presence or absence of mutations within the transthyretin protein and/or an individual’s ancestry.
Rose Pedretti, Lanie Wang, Justin L. Grodin, Ahmad Masri, Jeffery Kelly, Lorena Saelices   +5 more
openaire   +1 more source

ATTR: the forgotten kidney amyloidosis

Nephrology Dialysis Transplantation
ABSTRACT The main manifestation of wild-type transthyretin amyloidosis (wtATTR) is cardiac disease in the elderly. Kidney involvement is frequently underappreciated and has been dismissed as a functional consequence of heart failure.
Barbara Soler, Daria Abasheva, Alberto Ortiz   +2 more
openaire   +1 more source

Wild-Type ATTR Amyloidosis

Descrizione della amiloidosi cardiaca da ...
Perfetto, Federico, Cappelli, Francesco, Panichella, Giorgia, Argirò, Alessia, Maurer, Mathew S.   +4 more
openaire   +2 more sources

Conventional heart failure therapy in cardiac ATTR amyloidosis

European Heart Journal, 2023
Adam Ioannou, Alun Hughes, Nick Freemantle   +2 more
exaly  

Association between spinal stenosis and wild-type ATTR amyloidosis

Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021
Ellen McPhail, Denis Toskic, Knarik Arkun   +2 more
exaly  

Cardiac amyloidosis - ATTR

2022
openaire   +1 more source